ATRCMG2 Inhibitors
ATRCMG2 inhibitors are a class of chemical compounds designed to specifically inhibit the activity of ATRCMG2, a protein involved in cellular regulatory mechanisms. ATRCMG2 is thought to play a role in complex molecular pathways related to signal transduction and protein-protein interactions. By inhibiting ATRCMG2, these compounds interfere with its functional capacity, potentially impacting various cellular processes such as regulation of gene expression, protein modification, and intracellular signaling networks. The precise molecular targets of ATRCMG2 inhibitors are often specific domains within the protein that are crucial for its interaction with other molecules, thereby blocking its ability to execute its cellular functions effectively.
The study of ATRCMG2 inhibitors provides valuable insights into the broader functions of the protein within biological systems. Researchers use these inhibitors to dissect the specific pathways and cellular events in which ATRCMG2 is a key player, particularly focusing on how its inhibition alters cellular signaling and molecular dynamics. Blocking ATRCMG2 activity offers an opportunity to better understand its involvement in the regulation of cellular communication and coordination, as well as its role in maintaining cellular homeostasis. These inhibitors serve as important molecular tools for probing how ATRCMG2 fits into larger protein networks, revealing how its inhibition can influence various cellular processes that are critical for the function and stability of cellular systems. Through the use of ATRCMG2 inhibitors, scientists can further explore the intricacies of protein regulation and cellular signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This cytidine analog could induce hypermethylation of the ATRCMG2 gene promoter, leading to chromatin compaction and transcriptional silencing, thus reducing ATRCMG2 expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
By inhibiting histone deacetylases, Trichostatin A might prevent the deacetylation of histones associated with the ATRCMG2 gene, resulting in open chromatin and decreased ATRCMG2 transcription. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin intercalates into DNA and could disrupt the transcriptional machinery at the ATRCMG2 locus, leading to a blockade of ATRCMG2 mRNA synthesis and a consequent decrease in protein expression. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Although primarily an antibacterial agent, Rifampicin could theoretically inhibit human DNA-dependent RNA polymerase, downregulating ATRCMG2 mRNA transcription as an off-target effect. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
This compound binds to DNA at the transcription initiation complex, which could lead to a reduction in ATRCMG2 mRNA transcription by stalling RNA polymerase movement. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
By binding to the ATRCMG2 gene promoter, Mithramycin A might block transcription factor access, thus decreasing the initiation and elongation phases of ATRCMG2 transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin (Sirolimus) inhibits the mTOR pathway, which is crucial for cap-dependent translation initiation; this could reduce the overall level of ATRCMG2 protein synthesis. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
This antimalarial drug can disrupt endolysosomal function, potentially leading to the downregulation of ATRCMG2 expression by altering cellular signaling and trafficking that govern gene expression. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
This receptor tyrosine kinase inhibitor could downregulate ATRCMG2 expression by inhibiting pathways that promote angiogenesis and growth factor signaling that are upstream of ATRCMG2 gene activation. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate impedes folate metabolism, which is essential for nucleotide synthesis, thus potentially leading to a decrease in ATRCMG2 mRNA transcription due to limited nucleotide availability. | ||||||